Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TOP2A | P11388 | 7/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8842452 | 1.00 | CYP1A2 (0.42) | CYP1A2TOP2ACA1CA9DUT | |
| SCHEMBL8711625 | 1.00 | CYP1A2 (0.42) | CYP1A2TOP2ACA1CA9DUT | |
| SCHEMBL20211424 | 0.81 | TOP2A (0.45) | TOP2ADUTFKBP1A | |
| SCHEMBL8842221 | 0.80 | TOP2A (0.30) | TOP2A | |
| SCHEMBL8842224 | 0.80 | TOP2A (0.30) | TOP2A | |
| SCHEMBL18355374 | 0.77 | ALDH1A1 (0.48) | CYP1A2CA1CA9 | |
| SCHEMBL1739798 | 0.77 | SMYD2 (0.41) | CYP1A2TOP2ACA1CA9 | |
| SCHEMBL9128317 | 0.77 | SMYD2 (0.41) | CYP1A2TOP2ACA1CA9 | |
| SCHEMBL1740050 | 0.77 | SMYD2 (0.41) | CYP1A2TOP2ACA1CA9 | |
| SCHEMBL4772873 | 0.76 | LMNA (0.35) | TOP2ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20150241410-A1 | INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150241410-A1 | INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150239831-A1 | INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150239831-A1 | INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-5623081-A | USING BENZYLOXYACETALDEHYDE DIMETHYL ETHER, HALOGENATED 1-PHENYLMETHOXY-4-PENTEN-2-OL; CYCLIZATION | LIN YANG-I (US) | 1997-04-22 | — | — | US | disclosed |
| US-5602118-A | A 2-((2-SUBSTITUTED ALKYL)FUR-3-YL)-THIO-),3-CARBOXY-2-CARBOPENEM DERIVATIVES; EFFECTIVE AGAINST BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA | AMERICAN CYANAMID COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| US-5455351-A | Treating HIV or AIDS | ABBOTT LABORATORIES (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0466131-B1 | Pyranobenzoxadiazole derivatives | NISSAN CHEMICAL IND LTD (JP) | 1995-09-27 | — | — | EP | disclosed |
| EP-0617036-A2 | Novel 2-thiosubstituted carbapenems | AMERICAN CYANAMID COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5272271-A | Pyranobenzoxadiazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239831-A1 | INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2 | VIPR2, VIPR1, NTSR2 | CYP1A2 2954/4885TOP2A 4679/4885CA1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.